全文获取类型
收费全文 | 927篇 |
免费 | 56篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 33篇 |
妇产科学 | 12篇 |
基础医学 | 91篇 |
口腔科学 | 22篇 |
临床医学 | 93篇 |
内科学 | 174篇 |
皮肤病学 | 7篇 |
神经病学 | 55篇 |
特种医学 | 97篇 |
外科学 | 145篇 |
综合类 | 16篇 |
预防医学 | 82篇 |
眼科学 | 34篇 |
药学 | 74篇 |
肿瘤学 | 45篇 |
出版年
2022年 | 6篇 |
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 13篇 |
2018年 | 20篇 |
2017年 | 10篇 |
2016年 | 16篇 |
2015年 | 16篇 |
2014年 | 22篇 |
2013年 | 33篇 |
2012年 | 44篇 |
2011年 | 34篇 |
2010年 | 33篇 |
2009年 | 37篇 |
2008年 | 21篇 |
2007年 | 28篇 |
2006年 | 19篇 |
2005年 | 25篇 |
2004年 | 20篇 |
2003年 | 15篇 |
2002年 | 20篇 |
2001年 | 14篇 |
2000年 | 9篇 |
1999年 | 20篇 |
1998年 | 27篇 |
1997年 | 29篇 |
1996年 | 37篇 |
1995年 | 26篇 |
1994年 | 28篇 |
1993年 | 22篇 |
1992年 | 16篇 |
1991年 | 18篇 |
1990年 | 20篇 |
1989年 | 30篇 |
1988年 | 15篇 |
1987年 | 26篇 |
1986年 | 30篇 |
1985年 | 13篇 |
1984年 | 12篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 14篇 |
1980年 | 9篇 |
1979年 | 11篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 12篇 |
1975年 | 8篇 |
1970年 | 9篇 |
1966年 | 9篇 |
排序方式: 共有989条查询结果,搜索用时 46 毫秒
81.
Determination of aflatoxins in corn and peanuts using high performance liquid chromatography 总被引:1,自引:0,他引:1
Rodney W. Beaver 《Archives of environmental contamination and toxicology》1989,18(3):315-318
The various high performance liquid chromatographic techniques for the detection of aflatoxins in foodstuffs are examined. The need for resolution, selectivity, and sensitivity is emphasized and examples from the literature are used to illustrate this need. Examples include both normal and reversed-phase techniques. Sample cleanup, detection methods, chromatographic conditions, and pre- and post-column derivatization methods are discussed. 相似文献
82.
J D Seidman A J Yale-Loehr B Beaver C C Sun 《The American journal of surgical pathology》1991,15(7):695-698
A large hepatic cyst was excised from an infant who presented on the first day of life with an abdominal mass. Intraoperative, gross, and microscopic observations indicated that this was a cystic duplication of the ileum that extended into the liver. The cyst had a gastric mucosal lining, and there was evidence of ulceration. The occurrence of an alimentary duplication within the liver has been described in only one previous report. 相似文献
83.
Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia 总被引:1,自引:0,他引:1
Korbling M; Hunstein W; Fliedner TM; Cayeux S; Dorken B; Fehrentz D; Haas R; Ho AD; Keilholz U; Knauf W 《Blood》1989,74(6):1898-1904
Autologous bone marrow transplantation (ABMT) makes it possible to escalate the dose of cytotoxic treatment to a lethal range. Disease- free survival (DFS) following myeloablative therapy and ABMT has been shown to be superior to conventional treatment in high risk patients with acute myelogenous leukemia (AML). It was the purpose of the present study to compare hematopoietic reconstitution, actuarial DFS, and relapse rate of patients transplanted in first complete remission (CR) of AML with those in second or subsequent CR, and to evaluate transplant related mortality. Fifty-two patients with AML, 22 in first CR (low risk) and 30 in second or subsequent CR (high risk), underwent total body irradiation (12.1 to 16.7 Gy) and cyclophosphamide (CY) treatment (200 mg/kg) followed by ABMT. The autograft was incubated with the active CY derivative Mafosfamide (ASTA Werke, Bielefeld, Federal Republic of Germany) to reduce the number of possibly contaminating clonogenic tumor cells. All patients showed three lineage engraftments with platelet recovery observed as being the slowest. The transplant related death rate was low at 5.8%. There was no significant difference in the kinetics of polymorphonuclear (PMN) cell or platelet reconstitution between the low and high risk patient subgroups. The estimated probability of DFS (relapse) after ABMT in first CR was 61% (36%) compared with 34% (65%) in second or subsequent CR, the longest follow-up being 55 months and 57 months, respectively (median follow-up 31 months and 19 months, respectively). ABMT offers a stable long-term DFS when performed in first CR with no relapses occurring in over a year after transplantation. Six later relapses, however, were seen after ABMT in second or subsequent CR, although DFS was not statistically different from that of first remission patients (P = .72). 相似文献
84.
85.
S Lingam C Miller J Pateman R Beaver 《British medical journal (Clinical research ed.)》1986,292(6529):1183-1185
86.
J Punnose MD DM TM Yahya MD JS Premchandran MD HF Ahmed FRCP 《International journal of clinical practice》1997,51(7):468-470
We describe two type 2 diabetic patients with unilateral emphysematous pyelonephritis who responded to medical treatment alone. Escherichia coli was isolated in both patients. The presence of gas was confirmed early by ultrasound and CT scan of abdomen. Following treatment, good functional recovery was demonstrable in the affected kidneys by isotope renogram. We stress the need for early diagnosis of this condition and aggressive treatment with broad spectrum antibiotics. 相似文献
87.
Michael A. Mont Walter B. Beaver Stanley H. Dysart John W. Barrington Daniel J. Del Gaizo 《The Journal of arthroplasty》2018,33(1):90-96
Background
Local infiltration analgesia (LIA) with liposomal bupivacaine (LB) in patients undergoing total knee arthroplasty (TKA) has yielded mixed results. The PILLAR study, which was designed to minimize limitations associated with previous studies, compared the effects of LIA with or without LB on pain scores, opioid consumption, including proportion of opioid-free patients, time to first opioid rescue, and safety after primary unilateral TKA.Methods
Patients (N = 140) were randomized to LIA with LB 266 mg/20 mL (admixed with bupivacaine HCl 0.5%, 20 mL) or LIA with bupivacaine HCl 0.5%, 20 mL. Standardized infiltration techniques and a standardized multimodal pain management protocol were used. The coprimary efficacy endpoints were area under the curve (AUC) of visual analog scale pain intensity scores 12-48 hours (AUC12-48) postsurgery and total opioid consumption 0-48 hours postsurgery.Results
Mean AUC12-48 of visual analog scale pain intensity score was 180.8 with LB and 209.3 without LB (least squares [LS] mean treatment difference ?26.88, P = .0381). LS mean total opioid consumption 0-48 hours postsurgery was 18.7 mg with and 84.9 mg without LB (LS ratio 0.220, P = .0048). Significant differences in favor of LB were observed for the percentage of opioid-free patients (P < .01) and time to first opioid rescue (P = .0230). Treatments were similarly well tolerated.Conclusion
This study provides data on LIA with LB administered using optimal techniques specific to TKA. In this setting, LIA with LB significantly improved postsurgical pain, opioid consumption, and time to first opioid rescue, with more opioid-free patients and no unexpected safety concerns. 相似文献88.
目的:临床局部辐射条件下会造成非辐射区域组织及细胞功能损害,最为突出的是对造血功能的影响。实验建立60Coγ射线左半身辐射动物模型,观察局部电离辐射对其非辐射区域骨髓巨核细胞的影响。方法:实验于2003-10/2005-03在解放军第三军医大学辐照中心和全军复合伤研究所完成。①实验动物:6~8周龄SPF级雄性昆明小鼠180只,随机数字表法分为正常对照组、全身辐射组、左半身辐射组、全身屏蔽辐射组,45只/组。②实验方法:全身辐射组小鼠固定于辐射架内;左半身辐射组小鼠麻醉后固定体位,用铅砖屏蔽右半身;全身屏蔽辐射组小鼠麻醉固定体位,用铅砖屏蔽全身。以60Coγ射线一次性辐射,剂量率68.46cGy/min。正常对照组不作任何干预。③实验评估:辐射后不同时相检测小鼠血清丙二醛含量及超氧化物歧化酶活性变化,计数外周血血小板,检测骨髓巨核祖细胞集落形成单位,观察骨髓组织病理改变及CD41a、CD61的表达。结果:全身辐射组第8天死亡2只,第9天死亡4只,其余各组无脱失。①外周血血小板计数:辐射后第2,7天,左半身辐射组外周血血小板数量显著低于正常对照组(P<0.01),但高于全身辐射组(P<0.01)。②血清丙二醛含量及超氧化物歧化酶活性变化:辐射后第2,9天,左半身辐射组血清丙二醛含量显著高于正常对照组(P<0.01),低于全身辐射组(P<0.01);血清超氧化物歧化酶活性显著低于正常对照组(P<0.01),高于全身辐射组(P<0.01)。③骨髓巨核祖细胞集落形成单位的变化:与正常对照组比较,辐射后6h左半身辐射组非辐射侧的巨核祖细胞集落形成单位显著降低(P<0.01),高于全身辐射组及左半身辐射组(P<0.01)。④骨髓组织病理改变:正常对照组有核细胞比例较高,分布均匀,并见多量散在分布的细胞龛;辐射2d后,左半身辐射组非辐射侧骨髓有核细胞较正常对照组减少,但好于全身辐射组、左半身辐射组。⑤骨髓CD41a及CD61表达的变化:辐射后2d与正常对照组比较,左半身辐射组非辐射侧骨髓CD41a及CD61阳性细胞数和相对荧光强度均显著降低(P<0.01),但高于全身辐射组、左半身辐射组(P<0.01)。结论:局部电离辐射作用后,可导致小鼠非辐射区域骨髓巨核细胞增殖能力降低,血小板减少,产生功能障碍。氧自由基激活可能参与了该损伤过程。 相似文献
89.
David Walling Stephen R. Marder John Kane W. Wolfgang Fleischhacker Richard S. E. Keefe David A. Hosford Chris Dvergsten Anthony C. Segreti Jessica S. Beaver Steven M. Toler John E. Jett Geoffrey C. Dunbar 《Schizophrenia bulletin》2016,42(2):335-343
Objectives:
This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia.Methods:
In 64 sites in the United States, Russia, Ukraine, Hungary, Romania, and Serbia, 477 outpatients (18–65 years; male 62%; 55% tobacco users) with schizophrenia, treated with a new-generation antipsychotic, were randomized to 24 weeks of placebo (n = 235), TC-5619, 5mg (n = 121), or TC-5619, 50mg (n = 121), administered orally once daily. The primary efficacy measure was the Scale for the Assessment of Negative Symptoms (SANS) composite score. Key secondary measures were the Cogstate Schizophrenia Battery (CSB) composite score and the University of California San Diego Performance-Based Skills Assessment-Brief Version (UPSA-B) total score. Secondary measures included: Positive and Negative Syndrome Scale in Schizophrenia (PANSS) total and subscale scores, SANS domain scores, CSB item scores, Clinical Global Impression-Global Improvement (CGI-I) score, CGI-Severity (CGI-S) score, and Subject Global Impression-Cognition (SGI-Cog) total score.Results:
SANS score showed no statistical benefit for TC-5619 vs placebo at week 24 (5mg, 2-tailed P = .159; 50mg, P = .689). Likewise, no scores of CSB, UPSA-B, PANSS, CGI-I, CGI-S, or SGI-Cog favored TC-5619 (P > .05). Sporadic statistical benefit favoring TC-5619 in some of these outcome measures were observed in tobacco users, but these benefits did not show concordance by dose, country, gender, or other relevant measures. TC-5619 was generally well tolerated.Conclusion:
These results do not support a benefit of TC-5619 for negative or cognitive symptoms in schizophrenia.Key words: schizophrenia, negative symptoms, cognition 相似文献90.